Your browser doesn't support javascript.
loading
Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients / 中华肝脏病杂志
Chinese Journal of Hepatology ; (12): 881-886, 2009.
Artigo em Chinês | WPRIM | ID: wpr-247635
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the virological, serological and biochemical outcomes of 3 years of entecavir (ETV) treatment in nucleoside-naive chronic hepatitis B patients.</p><p><b>METHODS</b>This study was divided into two stages Patients receiving either ETV 0.5 mg/d (n = 258) or lamivudine (LAM) 100 mg/d (n = 261) entered the initial 96-week randomized, double blind, controlled efficacy study. Patients not achieving a consolidated response (HBV DNA less than 0.7 MEq/ml, ALT less than 1.25 times*ULN, and if HBeAg-positive at baseline, loss of HBeAg for >or= 24 weeks), or those experienced viral breakthrough or relapse, entered a 48-week entecavir rollover study.</p><p><b>RESULTS</b>96 weeks after the treatment, 79% of ETV treated and 46% of LAM treated patients had HBV DNA less than 300 copies/ml (P < 0.0001), 96% of ETV treated and 92% of LAM treated patients had normalized ALT (P = 0.06). 21% of ETV treated and 23% of LAM treated patients achieved HBeAg seroconversion. Among the 160 patients received continuous ETV for 144 weeks, 89% had undetectable serum HBV DNA, 86% showed ALT normalization, and 27% achieved HBeAg seroconversion. ETV resistance was rare only 3 patients showed ETV resistance 96 weeks after the treatment, and additional 2 patients developed ETV resistance during the following 48 weeks, genotyping indicated the ETV resistance was caused by gene mutation. Adverse event rates in ETV-treated patients were similar to those in LAM-treated patients, but fewer ALT flares were observed in ETV-treated patients.</p><p><b>CONCLUSIONS</b>This study demonstrates that ETV treatment results in long-term HBV suppression and ALT normalization in Chinese CHB patients, and is associated with low rate of drug resistance.</p>
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Antivirais / Fatores de Tempo / Virologia / Sangue / DNA Viral / Método Duplo-Cego / Resultado do Tratamento / Lamivudina / Carga Viral / Hepatite B Crônica Tipo de estudo: Ensaio Clínico Controlado Limite: Adolescente / Adulto / Idoso / Feminino / Humanos / Masculino Idioma: Chinês Revista: Chinese Journal of Hepatology Ano de publicação: 2009 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Antivirais / Fatores de Tempo / Virologia / Sangue / DNA Viral / Método Duplo-Cego / Resultado do Tratamento / Lamivudina / Carga Viral / Hepatite B Crônica Tipo de estudo: Ensaio Clínico Controlado Limite: Adolescente / Adulto / Idoso / Feminino / Humanos / Masculino Idioma: Chinês Revista: Chinese Journal of Hepatology Ano de publicação: 2009 Tipo de documento: Artigo